Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2025-06-25 Regulatory Filings
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing clinical regulatory advice from the EMA and a patent grant. It contains no financial results, no board/management changes, no dividend or financing news, and is not an investor presentation or detailed report. It does not fit any specific category and serves as a general announcement. Therefore it falls into the fallback category “Regulatory Filings (RNS).”
2025-06-25 English
News release - English.pdf
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing that the CEO will present at an external scientific conference. It contains no financial results, no management changes, no regulatory submission filings, no capital actions, no earnings data, and no AGM or proxy materials. It is not an investor slide deck or a detailed report but rather a general corporate announcement. As it does not fit any specific category, it falls into the fallback “Regulatory Filings” category (RNS).
2025-06-20 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate news release announcing activation of a second clinical site for a Phase 2 trial and providing operational updates. It contains forward-looking statements but no financial results, no regulatory form references, and no statutory filings. It is not an earnings release, interim or annual report, nor a financing or capital change notice. It is a general company announcement best classified under the fallback category for miscellaneous regulatory news announcements.
2025-06-17 English
News release - English.pdf
Regulatory Filings
2025-06-12 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing FDA clearance of an IND for a Phase 2a clinical trial. It contains no financial results, no meeting materials, no board or management changes, no dividends, no share transactions, and is not an offering, earnings release, or formal regulatory form like a 10-K or 8-K. It therefore falls into the fallback category for general regulatory announcements and miscellaneous filings.
2025-06-11 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 80% confidence The document is a NI 52-109 Form 52-109FV2 “Venture Issuer Basic Certificate” by the CEO certifying the interim financial report and interim MD&A for the period ended March 31, 2025. It is not the interim financial report itself, nor an earnings release, dividend notice, or other specific category—it is a regulatory certification form required by Canadian securities rules. It does not fit categories like IR (Interim Report) because it is only the certificate, nor AR (Audit Report) because it is not an auditor’s opinion. Thus it falls under the fallback “Regulatory Filings” category.
2025-05-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.